

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 June 2003 (26.06.2003)

PCT

(10) International Publication Number
WO 03/051870 A1

(51) International Patent Classification⁷: **C07D 409/12**,
409/14, 413/14, A61K 31/497, A61P 11/06, 29/00

(21) International Application Number: **PCT/SE02/02355**

(22) International Filing Date:
17 December 2002 (17.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0104474-2 18 December 2001 (18.12.2001) SE
0202139-2 5 July 2002 (05.07.2002) SE

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BAXTER, Andrew** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB). **JOHNSON, Timothy** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB). **KINDON, Nicholas** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB). **ROBERTS, Bryan** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB). **STEELE, John** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB). **STOCKS, Michael** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB). **TOMKINSON, Nicholas** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB).

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; AstraZeneca AB, S-151 85 Södertälje (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **NOVEL COMPOUNDS**



(57) Abstract: The invention provides N-pyrazinyl-thienylsulphonamides of formula (I) for use in the treatment of chemokine mediated diseases. Particularly inflammatory diseases, such as asthma.

WO 03/051870 A1

N-PYRAZINYL-THIENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES

The present invention relates to a sulphonamide compound, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

5

Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small-secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved
10 four cysteine motif. At the present time, the chemokine superfamily comprises three groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C), Cys-Cys (C-C) and Cys-X₃-Cys (C-X₃-C) families. The C-X-C and C-C families have sequence similarity and are distinguished from one another on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues. The C-X₃-C family is distinguished
15 from the other two families on the basis of having a triple amino acid insertion between the NH-proximal pair of cysteine residues.

The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).


20

The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils. Examples include human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins 1 α and 1 β (MIP-1 α and
25 MIP-1 β), Thymus and Activation Regulated Chemokine (TARC, CCL17) and Macrophage Derived Chemokine (MDC, CCL22). The C-X₃-C chemokine (also known as fractalkine) is a potent chemoattractant and activator of microglia in the central nervous system (CNS) as well as of monocytes, T cells, NK cells and mast cells.

30 Studies have demonstrated that the actions of chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX₃CR1 for the C-X₃-C family. These receptors represent good targets for
35 drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.

US patent 5,962,490 discloses a series of sulphonamide compounds said to be useful for treating endothelin mediated diseases. There is no specific disclosure of pyrazine sumphonamides and no mention of chemokine mediated diseases.

The present invention therefore provides a compound of formula (I) and pharmaceutically acceptable salts or solvates thereof:



(I)

in which:

R¹, R² and R³ are independently hydrogen, halogen, cyano, CF₃, or C₁₋₆ alkyl;

R⁴ is halogen, CO₂R¹²,

C₁₋₆ alkoxy where the alkyl group may form a 3-6 membered saturated ring or may be substituted with 1-3 fluorine atoms or a cyano group;

C₃₋₆ alkenyloxy or C₃₋₆ alkynyloxy where either may be optionally substituted with hydroxy or NR¹⁴R¹⁵;

OC₁₋₆ alkyl-X-C₁₋₆ alkyl where the alkyl groups may form a 3-6 membered saturated ring;

OC₁₋₆ alkylR¹¹, or OC₂₋₆ alkyl-X-R¹¹ where the alkyl group may form a 3-6 membered saturated ring and is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR¹⁴R¹⁵, SR¹³, S(O)₂R¹³, S(O)R¹³;

OC₁₋₆ alkylR¹⁶;

R⁵ and R⁶ are independently hydrogen, cyano, halogen, CO₂R¹², CONR¹⁴R¹⁵;

C₁₋₆ alkyl optionally substituted by hydroxy, NR¹⁴R¹⁵, or 1-3 fluorines;

C₁₋₆ alkylR¹¹ or XCH(R¹¹)C₁₋₆ alkyl or XCH(R¹⁶)C₁₋₆ alkyl where the alkyl group may be optionally substituted with 1-3 groups selected from hydroxy, and NR¹⁴R¹⁵;

NR¹⁴R¹⁵; N(R¹¹)R¹¹; X-(CH₂)_qNR¹⁴R¹⁵; (CH₂)_nNR¹⁴R¹⁵;

C₃₋₆ alkynyl or C₃₋₆ alkenyl optionally branched and optionally substituted with 1-3 groups selected from hydroxy, cyano, halogen and =O;

R¹¹; X-R¹¹; X-R¹²; X-C₁₋₆alkylR¹⁶; X-R¹⁶; X-(CH₂)_nCO₂R¹²; X-(CH₂)_nCONR¹⁴R¹⁵;
X-(CH₂)_nR¹¹; X-(CH₂)_nCN; X-(CH₂)_qOR¹²; (CH₂)_nOR¹²;
(CH₂)_n-X-R¹¹; X-(CH₂)_qNHC(O)NHR¹²; X-(CH₂)_qNHC(O)R¹²;
X-(CH₂)_qNHS(O)₂R¹²; X-(CH₂)_qNHS(O)₂R¹¹; X-C₃₋₆alkenyl; X-C₃₋₆alkynyl;

n is 1, 2, 3, 4 or 5;

q is 2, 3, 4, 5 or 6;

X is NR¹³, O, S, S(O), S(O)₂;

R¹¹ is an aryl group or a 5-7 membered heteraromatic ring containing 1-4 heteroatoms selected from nitrogen, oxygen or sulphur each of which can be optionally substituted by 1-3 groups selected from halogen, C(O)NR¹⁴R¹⁵, C(O)OR¹², hydroxy, =O, =S, CN, NO₂, NR¹⁴R¹⁵, X(CH₂)_qNR¹⁴R¹⁵, (CH₂)_nNR¹⁴R¹⁵, (CH₂)_nOH, SR¹³, S(O)R¹³, S(O)₂R¹³, C₁₋₆ alkyl-X-C₁₋₆ alkyl, C₁₋₆ alkyl or C₁₋₆ alkoxy where the alkyl group may form a 3-6 membered ring or is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR¹⁴R¹⁵, SR¹³, S(O)R¹³, S(O)₂R¹³;

R¹² and R¹³ are independently hydrogen or C₁₋₆ alkyl where the alkyl group may be substituted with 1-3 fluorine atoms or may form a saturated 3-6 membered ring;

R¹⁴ and R¹⁵ are independently hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl or (CH₂)_qOH,

or R¹⁴ and R¹⁵ together with the nitrogen atom to which they are attached form a 4-8 membered saturated ring containing 1-3 heteroatoms selected from nitrogen, oxygen and sulphur and optionally substituted by C₁₋₆ alkyl, C₁₋₆ alkyl-OH, or hydroxy; and

- 5 R¹⁶ is a 4-8 membered saturated ring containing 1-3 heteroatoms selected from nitrogen, oxygen or sulphur and optionally substituted with 1-3 groups selected from hydroxy, cyano, halogen and =O,

The term aryl includes phenyl and naphthyl. The term alkyl, whether alone or as part of
10 another group, includes straight chain and branched chain alkyl groups. Examples of 5- to 7-membered heteroaromatic ring containing 1 to 4 heteroatoms include thienyl, furanyl, pyrrolyl, imidazolyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl, triazinyl, oxazolyl, thiazolyl, isoxazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl. Examples of saturated 4- to 8-membered rings containing 1 to 3 heteroatoms include
15 morpholine, piperidine and azetidine. Substituents on any rings can be present in any suitable ring position including suitable substituents on nitrogen atoms.

Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the
20 compounds of formula (I) and mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect of the present invention.

Preferably the thienyl moiety is linked to the sulphonamide at the 2-position of the thiophene ring.

25


Preferred halogen groups for R¹, R² and R³ are chloro or bromo. Preferably R¹, R² and R³ are all hydrogen or two are hydrogen and the other is chloro, bromo or methyl. More preferably R² and R³ are hydrogen and R¹ is chloro at the 5-position of the thienyl ring.

- 30 For the group R⁴ examples of C₃₋₆ alkenyloxy include OCH₂CH=CH₂, examples of C₃₋₆ alkynyloxy include OCH₂CCH, examples of OC₁₋₆ alkyl-O-C₁₋₆ alkyl include OCH₂CH₂OMe, examples of OC₁₋₆ alkylR¹¹ include OCH₂R¹¹, and examples of OC₁₋₆ alkylR¹⁶ include OCH₂pyrrolidine.


- 35 Preferred groups for R⁴ include C₁₋₆ alkoxy such as methoxy and ethoxy, phenoxy, 2-furanylmethoxy, bromo, 2-methoxyethoxy, (5-methyl-3-isoxazolyl)methoxy, 2-

pyridylmethoxy, 3-pyridazinylmethoxy, methoxy, 2-(1-imidazolyl)ethoxy and 4-methoxyphenylmethoxy. More preferably R^4 is methoxy or pyridylmethoxy. Most preferably R^4 is methoxy.

- For R^5 and R^6 examples of $NR^{14}R^{15}$ includes morpholine, pyrrolidine, NMe_2 , $NHCH_2CH_2OMe$, $NHMe$, and the groups below:



- Examples of $X-(CH_2)_qNR^{14}R^{15}$ includes $SCH_2CH_2NH_2$ and $SCH_2CH_2NMe_2$, examples of $(CH_2)_nNR^{14}R^{15}$ include CH_2 morpholine, examples of $X-R^{12}$ includes SMe , OMe , OEt , OH , SO_2Me , examples of $X-C_{1-6}alkylR^{16}$ includes OCH_2 pyrrolidine, examples of $X-(CH_2)_nCO_2R^{12}$ includes SCH_2CO_2H , SCH_2CO_2Me , $SCH_2CH_2CO_2Me$, examples of $X-(CH_2)_nCONR^{14}R^{15}$ includes SCH_2CONH_2 , $SCH_2CONHMe$, SCH_2CONMe_2 , examples of $X-(CH_2)_nR^{11}$ includes the groups below:



- Examples of $X-(CH_2)_nCN$, includes SCH_2CN , examples of $X-(CH_2)_qOR^{12}$ includes OCH_2CH_2OMe , examples of $(CH_2)_nOR^{12}$ includes CH_2OH , CH_2OMe , examples of $X-(CH_2)_qNHC(O)NHR^{12}$ includes $SCH_2CH_2NHC(O)NHMe$, and examples of $X-(CH_2)_qNHC(O)R^{12}$ includes $NHCH_2CH_2NHC(O)Me$.

- Preferred groups for R^5 include hydrogen, halogen such as bromo and chloro, phenyl, C_{1-6} alkyl such as methyl, cyano and 2-aminothianethiol. More preferably R^5 is hydrogen, methyl or halogen such bromo or chloro.

Preferred groups for R^6 include hydrogen, C_{1-6} alkyl and halogen, more preferably hydrogen, methyl, and chloro.

Preferred compounds of formula (I) include:

- N-(5-Bromo-3-methoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide
N-(5-Bromo-3-ethoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide
N-(5-Bromo-3-methoxy-2-pyrazinyl)-4,5-dichloro-2-thiophenesulphonamide
5-Chloro-N-(3-methoxy-5-phenyl-2-pyrazinyl)-2-thiophenesulphonamide
5 N-(5-Bromo-3-phenoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide
N-(5-Bromo-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide
N-[5-Bromo-3-(2-furanylmethoxy)-2-pyrazinyl]-5-chloro-2-thiophenesulphonamide
5-Chloro-N-(3,5-dibromo-2-pyrazinyl)-2-thiophenesulphonamide
5-Chloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-2-thiophenesulphonamide
10 5-Chloro-N-(5-chloro-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide
5-Bromo-N-(5-bromo-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide
5-Chloro-N-(6-chloro-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide
3-Bromo-N-(5-bromo-3-methoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide
N-(5-Bromo-3-methoxy-2-pyrazinyl)-3-thiophenesulphonamide
15 5-Chloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide
5-Chloro-N-[5-bromo-3-(2-methoxyethoxy)-2-pyrazinyl]-2-thiophenesulphonamide
5-Chloro-N-[5-bromo-3-[2-(1-imidazolyl)ethoxy]-2-pyrazinyl]-2-thiophenesulphonamide
5-Bromo-N-(6-chloro-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide
5-Bromo-N-(5-chloro-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide
20 5-Chloro-N-[6-chloro-3-(2-furanylmethoxy)-2-pyrazinyl]-2-thiophenesulphonamide
5-Chloro-N-[6-chloro-3-(5-methyl-3-isoxazolylmethoxy)-2-pyrazinyl]-2-thiophenesulphonamide
5-Chloro-N-[6-chloro-3-(2-pyridinylmethoxy)-2-pyrazinyl]-2-thiophenesulphonamide
5-Chloro-N-[5-methyl-3-(3-pyridinylmethoxy)-2-pyrazinyl]-2-thiophenesulphonamide
25 5-Chloro-N-[5-methyl-3-(3-pyridazinylmethoxy)-2-pyrazinyl]-2-thiophenesulphonamide
5-Chloro-N-[3-(2-pyridinylmethoxy)-2-pyrazinyl]-2-thiophenesulphonamide
5-Chloro-N-(3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide
5-Chloro-N-(5,6-dimethyl-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide
N-[5-Chloro-3-methoxy-2-pyrazinyl]-5-methyl-2-thiophenesulphonamide
30 5-Methyl-N-[5-methyl-3-methoxy-2-pyrazinyl]-2-thiophenesulphonamide
N-[5-((2-Aminoethyl)sulpanyl)-3-methoxy-2-pyrazinyl]-5-chloro-2-thiophenesulphonamide
5-Chloro-N-[5-cyano-3-methoxy-2-pyrazinyl]-2-thiophenesulphonamide
N-[5-Bromo-3-(4-methoxybenzyloxy)-2-pyrazinyl]-5-chloro-2-thiophenesulphonamide
35 and pharmaceutically acceptable salts and solvates thereof.

A preferred sub-class of compounds of formula (I) are compounds (IA) where

R^1 , R^2 and R^3 are independently hydrogen, C_{1-6} alkyl or halogen;

R^4 is halogen, C_{1-6} alkoxy or OR^9 ;

R^5 and R^6 are independently hydrogen, halogen, C_{1-6} alkoxy, C_{1-6} alkylthio, cyano, R^9 ,

5 OR^9 , NR^9R^{10} , SR^9 , $S(CH_2)_nCO_2H$, $S(CH_2)_nCO_2R^{12}$, $S(CH_2)_nCONR^{12}R^{13}$, $S(CH_2)_nR^{11}$ or a 5- to 7-membered heteroaromatic or saturated ring containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulphur;

n is 1, 2 or 3;

R^9 and R^{10} are independently hydrogen, C_{1-6} alkyl optionally substituted by hydroxy, C_{1-6}
10 alkoxy or $NHCOC_{1-6}$ alkyl, or R^9 and R^{10} are optionally substituted aryl, C_{1-6} alkyl-aryl or C_{1-6} alkyl- R^{11} or R^9 and R^{10} together with the nitrogen atom to which they are attached form a 4- to 8-membered saturated ring containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulphur and optionally substituted by C_{1-6} alkyl or C_{1-6} alkyl-OH; and R^{11} is a 5- to 7-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from
15 nitrogen, oxygen and sulphur and optionally substituted by C_{1-6} alkyl; and R^{12} and R^{13} are independently hydrogen or C_{1-6} alkyl.

For sub-class (IA) the thienyl moiety is preferably linked to the sulphonamide at the
20 2-position.

For sub-class (IA) R^1 , R^2 and R^3 are independently hydrogen, C_{1-6} alkyl or halogen,
25 preferred halogen groups being chloro or bromo. Preferably R^1 , R^2 and R^3 are all hydrogen or two are hydrogen and the other is chloro, bromo or methyl. More preferably R^2 and R^3 are hydrogen and R^1 is chloro at the 5-position of the thienyl ring.


For sub-class (IA) preferred groups for R^4 include C_{1-6} alkoxy such as methoxy and
30 ethoxy, phenoxy, 2-furanylmethoxy, bromo, 2-methoxyethoxy, (5-methyl-3-isoxazolyl)methoxy, 2-pyridylmethoxy, 3-pyridazinylmethoxy, methoxy, and 2-(1-imidazolyl)ethoxy.

For sub-class (IA) preferred groups for R^5 include hydrogen, halogen such as bromo and
35 chloro, phenyl and C_{1-6} alkyl such as methyl.

For sub-class (IA) preferred groups for R^6 include hydrogen, C_{1-6} alkyl and halogen, more
preferably hydrogen, methyl and chloro.

For sub-class (IA) preferred compounds include those of examples 1 to 32 exemplified herein, both in free acid form and in the form of pharmaceutically acceptable salts.


According to the invention there is also provided a process for the preparation of compound (I) which comprises reaction of a compound of formula (II):



(II)

10

where R⁴, R⁵ and R⁶ are as defined in formula (I) or are protected derivatives thereof with a compound of formula (III):



15

(III)

where R¹, R² and R³ are as defined in formula (I) or are protected derivatives thereof and LG is a leaving group, and optionally thereafter:

20

- removing any protecting groups,
- forming a pharmaceutically acceptable salt.

Preferred leaving groups LG include halogen such as chloro. Preferably the reaction between compounds (II) and (III) is carried out by treating compound (II) with a base such as sodium hydride or potassium tert-butoxide in a suitable solvent such as 1,2-dimethoxyethane or tetrahydrofuran.


Where R⁴ is C₁₋₆ alkoxy where the alkyl group may form a 3-6 membered saturated ring or may be substituted with 1-3 fluorine atoms or a cyano group;
C₃₋₆ alkenyloxy or C₃₋₆ alkynyloxy where either may be optionally substituted with hydroxy or NR¹⁴R¹⁵;

30

OC₁₋₆ alkyl-X-C₁₋₆ alkyl where the alkyl groups may form a 3-6 membered saturated ring;
 OC₁₋₆ alkylR¹¹, or OC₂₋₆ alkyl-X-R¹¹ where the alkyl group may form a 3-6 membered
 saturated ring and is optionally substituted with 1-3 groups selected from hydroxy,
 halogen, NR¹⁴R¹⁵, SR¹³, S(O)₂R¹³, S(O)R¹³; or

5 OC₁₋₆ alkylR¹⁶;

compounds of formula (II) can be prepared by treating a compound of the formula (IV),
 where LG is a leaving group (such as chlorine or bromine):



10 (IV)

with a compound of formula (V)

R⁴-H

15

(V)

in a suitable solvent (such as 1,2-dimethoxyethane, *N,N*-dimethylformamide or
 tetrahydrofuran) with a suitable base such as sodium hydride or potassium tert-butoxide
 20 at a suitable temperature such as 25°C to 60°C.


Where R⁴ is C₁₋₆ alkoxy where the alkyl group may form a 3-6 membered saturated ring or
 may be substituted with 1-3 fluorine atoms or a cyano group;

C₃₋₆ alkenyloxy or C₃₋₆ alkynyloxy where either may be optionally substituted with
 25 hydroxy or NR¹⁴R¹⁵;

OC₁₋₆ alkyl-X-C₁₋₆ alkyl where the alkyl groups may form a 3-6 membered saturated ring;
 OC₁₋₆ alkylR¹¹, or OC₂₋₆ alkyl-X-R¹¹ where the alkyl group may form a 3-6 membered
 saturated ring and is optionally substituted with 1-3 groups selected from hydroxy,
 halogen, NR¹⁴R¹⁵, SR¹³, S(O)₂R¹³, S(O)R¹³; or

30 OC₁₋₆ alkylR¹⁶;

compounds of formula (I) can be prepared by treating a compound of the formula (VI), where LG is a leaving group (such as chlorine or bromine):




5 (VI)

with a compound of formula (V)

in a suitable solvent (such as 1,2-dimethoxyethane, *N,N*-dimethylformamide or
10 tetrahydrofuran) with a suitable base such as sodium hydride or potassium tert-butoxide
at a suitable temperature such as 25°C to 60°C.

Compounds of structure (VIII) can be prepared by taking a compound of formula (VII)
where LG is a leaving group (such as chlorine or bromine) and protecting the sulfonamide
15 as for example the trimethylsilyloxymethyl ether (SEM) or methoxymethyl ether
(MOM) by the standard literature methods (such as SEM-chloride or MOM-chloride in a
suitable solvent (such as tetrahydrofuran) with a suitable base (such as triethylamine) at a
suitable temperature (such as 0-20°C) to afford compound of the formula (VIII):

11




Compound of formula (VIII) could then be treated with compounds of formulae (IX):

R^5-H


(IX)

where R^5-H is a primary or secondary amine, thiol or alcohol as defined above (i.e. where R^5 is a group containing an X moiety where X is NR^{13} , O or S), in a suitable solvent (such as tetrahydrofuran or acetonitrile) with or without a suitable base (such as sodium hydride, caesium carbonate or triethylamine) at a suitable temperature ranging from 25-85°C to afford compound of the formula (X):




The protecting group (P) can then be removed by standard methods to afford compound of formula (I).


Compounds of structure (II) or (I), where R^5 is an optionally substituted aryl or heteroaryl ring as defined in the claims, can be prepared by taking a compound of formula (XI) or (VII) where LG is a suitable leaving group such as bromine, chlorine or iodine and reacting it with an aryl or heteroaryl boronic acid such as phenyl boronic acid, a palladium catalyst such as [1,1'-bis(diphenylphosphino)ferrocene]palladium (II) chloride, a suitable base such as cesium fluoride, sodium acetate or cesium carbonate and a suitable solvent such as methanol or ethanol and heating between 40-80°C




(XI)



(II)



(VII)



(I)

Compounds of formula (II) and (I) where R^5 or R^6 is CO_2R^{13} can be prepared by reacting a compound of formula (II) or (I), where R^5 or R^6 is bromine or iodine, in a suitable solvent such as R^{13}OH or dioxane containing R^{13}OH , a suitable tertiary amine such as triethylamine, a suitable palladium catalyst such as [1,1'-bis(diphenylphosphino)ferrocene]palladium (II) chloride under an atmosphere of carbon monoxide usually at 2-10 barr, ideally at 4-6 barr and at a temperature of 70-120 °C.

Compounds of formula (II) and (I) where R^5 or R^6 is $CONR^{14}R^{15}$ can be prepared by reacting a compound of formula (II) or (I), where R^5 or R^6 is bromine or iodine, in a suitable solvent such as dioxane containing $NHR^{14}R^{15}$, a suitable tertiary amine such as triethylamine, a suitable palladium catalyst such as [1,1'-

5 bis(diphenylphosphino)ferrocene]palladium (II) chloride under an atmosphere of carbon monoxide usually at 2-10 barr, ideally at 4-6 barr and at a temperature of 70-120 °C.

Compounds of formula (I) where R^5 or R^6 is CH_2OH can be prepared from compounds of formula (I) where R^5 or R^6 is CO_2R^{13} by reduction using a suitable reducing agent such as lithium triethylborohydride in a suitable solvent such as tetrahydrofuran at a temperature of
10 0-10°C.

Compounds of formula (I) where R^5 or R^6 is CHO can be prepared from compounds of formula (I) where R^5 or R^6 is CH_2OH by oxidation using a suitable oxidising agent such as manganese dioxide or pyridinium chlorochromate (PCC) in a suitable solvent such as tetrahydrofuran or dichloromethane at a temperature of 0-50°C.

15 Compounds of formula (I) where R^5 or R^6 is $CH(OH)R^{11}$ or $CH(OH)(C1-5)alkyl$ can be prepared from compounds of formula (I) where R^5 or R^6 is CHO by reaction with a compound of formula (XII) where M is a metal such as magnesium or lithium in a suitable solvent such as tetrahydrofuran or diethyl ether at a temperature of 0-10°C

20 $C_{1-5} alkylM$ or $R^{11}M$

(XII)

Intermediate compounds of formula (II) and (III) can be prepared using standard chemistry
25 or are available commercially.

It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups such as hydroxyl or amino groups in the starting
30 reagents or intermediate compound may need to be protected by protecting groups. Thus, the preparation of the compound of formula (I) may involve, at an appropriate stage, the removal of one or more protecting groups. The protection and deprotection of functional groups is fully described in 'Protective Groups in Organic Chemistry', edited by J. W. F. McOmie, Plenum Press (1973), and 'Protective Groups in Organic Synthesis', 2nd edition,
35 T. W. Greene & P. G. M. Wuts, Wiley-Interscience (1991).

The compounds of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably a basic addition salt such as sodium, potassium, calcium, aluminium, lithium, magnesium, zinc, benzathine, chlorprocaine, choline, diethanolamine, ethanolamine, ethyldiamine, meglumine, tromethamine or procaine, or an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or *p*-toluenesulphonate.

The compounds of formula (I) has activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially CCR4) activity, and may be used in the treatment (therapeutic or prophylactic) of conditions/diseases in human and non-human animals which are exacerbated or caused by excessive or unregulated production of chemokines. Examples of such conditions/diseases include:

- (1) **(the respiratory tract)** obstructive airways diseases including chronic obstructive pulmonary disease (COPD); asthma, such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness); bronchitis; acute, allergic, atrophic rhinitis and chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous and pseudomembranous rhinitis and scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) and vasomotor rhinitis; sarcoidosis, farmer's lung and related diseases, fibroid lung and idiopathic interstitial pneumonia;
- (2) **(bone and joints)** gout, rheumatoid arthritis, seronegative spondyloarthropathies (including ankylosing spondylitis, psoriatic arthritis and Reiter's disease), Behcet's disease, Sjogren's syndrome and systemic sclerosis;
- (3) **(skin)** pruritis, scleroderma, otitis, psoriasis, atopic dermatitis, contact dermatitis and other eczmatous dermatides, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides, erythemas, cutaneous eosinophilias, uveitis, Alopecia areata and vernal conjunctivitis, lupus;
- (4) **(gastrointestinal tract)** Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, inflammatory bowel diseases such as Crohn's disease, ulcerative

colitis, ileitis and enteritis, food-related allergies which have effects remote from the gut, e.g., migraine, rhinitis and eczema;

(5) **(central and peripheral nervous system)** Neurodegenerative diseases and dementia disorders, e.g. Alzheimer's disease, amyotrophic lateral sclerosis and other motor neuron diseases, Creutzfeldt-Jacob's disease and other prion diseases, HIV encephalopathy (AIDS dementia complex), Huntington's disease, frontotemporal dementia, Lewy body dementia and vascular dementia; polyneuropathies, e.g. Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, plexopathies; CNS demyelination, e.g. multiple sclerosis, acute disseminated/haemorrhagic encephalomyelitis, and subacute sclerosing panencephalitis; neuromuscular disorders, e.g. myasthenia gravis and Lambert-Eaton syndrome; spinal disorders, e.g. tropical spastic paraparesis, and stiff-man syndrome; paraneoplastic syndromes, e.g. cerebellar degeneration and encephalomyelitis; CNS trauma; migraine; stroke and correctum diseases such as meningitis

(6) **(other tissues and systemic disease)** hepatitis, vasculitis, spondyloarthropathies, vaginitis, glomerulonephritis, myositis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), lupus erythematosus, systemic lupus, erythematosus, Hashimoto's thyroiditis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, lepromatous leprosy, and idiopathic thrombocytopenia pupura; post-operative adhesions, and sepsis.

(7) **(allograft and xenograft rejection)** acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin and cornea; and chronic graft versus host disease;

(8) **Cancer, carcinoma & tumour metastasis**, including that of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid and skin, especially non-small cell lung cancer (NSCLC), malignant melanoma, prostate cancer and squamous sarcoma. Hematopoietic tumors of lymphoid lineage, including acute lymphocytic leukemia, B cell lymphoma and Burkett's lymphoma, Hodgkins Lymphoma, Acute Lymphoblastic Leukemia.

Hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias and promyelocytic leukemia. Tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma, and other tumors, including melanoma, seminoma, tetratocarcinoma, neuroblastoma and glioma.

5

(9) All diseases that result from a general imbalance of the immune system and resulting in increased atopic inflammatory reactions.

10

(10) Cystic fibrosis, re-perfusion injury in the heart, brain, peripheral limbs and other organs.

(11) Burn wounds & chronic skin ulcers

15

(12) Reproductive Diseases (e.g. Disorders of ovulation, menstruation and implantation, Pre-term labour, Endometriosis)

(13) thrombosis

20

(14) infectious diseases such as HIV infection and other viral infections, bacterial infections.

Thus, the present invention provides a compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.

25

Preferably the compound of the invention are used to treat diseases in which the chemokine receptor belongs to the CC chemokine receptor subfamily, more preferably the target chemokine receptor is the CCR4 receptor.

30

Particular conditions which can be treated with the compound of the invention are asthma, rhinitis and inflammatory skin disorders, diseases in which there are raised TARC, MDC or CCR4 levels. It is preferred that the compound of the invention is used to treat asthma and rhinitis, especially asthma.

35

In a further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

In a still further aspect, the present invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity, particularly CCR4 activity, is beneficial.

In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

The invention still further provides a method of treating a chemokine mediated disease wherein the chemokine binds to a chemokine (especially CCR4) receptor, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.

The invention also provides a method of treating a respiratory disease, such as asthma and rhinitis, especially asthma, in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.


For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated.

The compound of formula (I) and pharmaceutically acceptable salts and solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

The present invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

- 5 The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined, with a pharmaceutically acceptable adjuvant, diluent or carrier.
- 10 The pharmaceutical compositions may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration
- 15 in the form of suppositories or transdermally. Preferably the compound of the invention is administered orally.

The following examples illustrate the invention.

Example 1***N*-(5-Bromo-3-methoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide**

5


5-Bromo-3-methoxy-2-pyrazinamine (1.0g) in 1,2-dimethoxyethane (10mL) was added to a stirred suspension of sodium hydride (0.48g of 60%) in 1,2-dimethoxyethane (10mL) under nitrogen at room temperature. 5-Chloro-2-thienylsulphonyl chloride (1.1g) in 1,2-dimethoxyethane (10mL) was added dropwise over 30 minutes. After 1 hour, aqueous citric acid (50mL of 5%) was added and the product extracted with ethyl acetate (X3). The combined extracts were washed with saturated brine, dried (MgSO₄) and the solvent was evaporated. Chromatography on silica eluting with dichloromethane gave the title compound as a white solid (1.2g).

10

m/e 382/4/6 (M-1⁺, 100%),

15

¹H NMR (D6-DMSO) δ 8.08 (1H, s), 7.67 (1H, d), 7.24 (1H, d), 3.93 (3H, s).


Example 2***N*-(5-Bromo-3-ethoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide**

20

Prepared by the method of Example 1 from 5-bromo-3-ethoxy-2-pyrazinamine.

m/e 396/8/400 (M-1⁺, 100%),


¹H NMR (D6-DMSO) δ 8.05 (1H, s), 7.69 (1H, d), 7.25 (1H, d), 4.35 (2H, q), 1.37 (3H, t).

Example 3***N*-(5-Bromo-3-methoxy-2-pyrazinyl)-4,5-dichloro-2-thiophenesulphonamide**

Prepared by the method of Example 1 from 4,5-dichlorothiophenesulphonyl chloride.

m/e 416/8/20/2 ($M-1^+$, 100%),

^1H NMR (D6-DMSO) δ 8.08 (1H, s), 7.81 (1H, s), 3.93 (3H, s).

Example 4***5*-Chloro-*N*-(3-methoxy-5-phenyl-2-pyrazinyl)-2-thiophenesulphonamide**

10

(a) 3-Methoxy-5-phenyl-2-pyrazinamine

5-Bromo-3-methoxy-2-pyrazinamine (0.31g), cesium fluoride (0.8g), benzenboronic acid (0.36g) and [1,1'-bis(diphenylphosphino)ferrocene]palladium (II) chloride (0.08g) in methanol (7mL) was heated at reflux for 2 hours. The solvent was evaporated and the residue purified by chromatography on silica eluting with toluene/ethyl acetate mixtures to give the sub-title compound (0.25g).

15

m/e 202 ($M+1^+$, 100%),

^1H NMR (D6-DMSO) δ 8.1 (1H, s), 7.91 (2H, d), 7.42 (2H, t), 7.28 (1H, t), 6.43 (2H, s), 4.0 (3H, s).

20


(b) 5-Chloro-*N*-(3-methoxy-5-phenyl-2-pyrazinyl)-2-thiophenesulphonamide

Prepared by the method of Example 1 from 3-methoxy-5-phenyl-2-pyrazinamine.

m/e 380/2 ($M-1^+$, 100%),

^1H NMR (D6-DMSO) δ 8.5 (1H, s), 8.05 (2H, d), 7.70 (1H, d), 7.55-7.40 (3H, m), 7.25 (1H, d), 4.04 (3H, s).

25

Example 5***N*-(5-Bromo-3-phenoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide**

5 (a) 5-Bromo-3-phenoxy-2-pyrazinamine

Sodium phenoxide trihydrate (0.5g) and 3,5-dibromo-2-pyrazinamine (0.5g) in acetonitrile (20mL) were heated at reflux for 7 hours. After cooling, water was added and the reaction mixture extracted with ethyl acetate (x2). The combined extracts were dried (MgSO₄) and the solvent evaporated to give the sub-title compound as a white solid.


10 m/e 266/8 (M+1⁺, 25%), HPLC 98%

¹H NMR (D6-DMSO) δ 7.75 (1H, s), 7.45 (2H, t), 7.25 (3H, m) and 6.84 (2H, s).

(b) *N*-(5-Bromo-3-phenoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide

Prepared by the method of Example 1 using the compound of Example 5a.


m/e 444/6/8 (M-1⁺, 100%),

15 ¹H NMR (D6-DMSO) δ 8.24 (1H, s), 7.73 (1H, d), 7.47 (2H, t), 7.27 (4H, m).**Example 6*****N*-(5-Bromo-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide**

20 Prepared by the method of Example 1 from 2-thienylsulphonyl chloride.

m/e 348/50 (M-1⁺, 100%),

¹H NMR (D6-DMSO) δ 11.34 (1H, s), 8.03 (1H, s), 7.97 (1H, d), 7.80 (1H, d), 7.18-7.15 (1H, m), 3.93 (3H, s).

Example 7***N*-[5-Bromo-3-(2-furanylmethoxy)-2-pyrazinyl]-5-chloro-2-thiophenesulphonamide****(a) 5-Bromo-3-(2-furanylmethoxy)-2-pyrazinamine**


5 Prepared by the method of Example 20a from 2-furanylmethanol and sodium hydride in 1,2-dimethoxyethane and used directly in step 7b

(b) *N*-[5-Bromo-3-(2-furanylmethoxy)-2-pyrazinyl]-5-chloro-2-thiophenesulphonamide

Prepared by the method of Example 1 using the compound of Example 7a.

m/e 448/50/2 ($M-1^+$, 100%),

10 ^1H NMR (D6-DMSO) δ 8.12 (1H, s), 7.74 (1H, dd), 7.65 (1H, d), 7.23 (1H, d), 6.65 (1H, dd), 6.51 (1H, dd), 5.35 (2H, s).


Example 8**5-Chloro-*N*-(3,5-dibromo-2-pyrazinyl)-2-thiophenesulphonamide**

15 Prepared by the method of Example 1 from 3,5-dibromo-2-pyrazinamine.

m/e 430/2/4/6 ($M-1^+$, 100%),

^1H NMR (D6-DMSO) δ 8.54 (1H, s), 7.62 (1H, d), 7.21 (1H, d).

20 Example 9**5-Chloro-*N*-(3-methoxy-5-methyl-2-pyrazinyl)-2-thiophenesulphonamide**



Prepared by the method of Example 1 from 3-methoxy-5-methyl-2-pyrazinamine.


m/e 318/20 ($M-1^+$, 100%),

^1H NMR (D6-DMSO) δ 11.1 (1H, s), 7.77 (1H, s), 7.63 (1H, d), 7.22 (1H, d), 3.89 (3H, s),

2.33 (3H, s).

Example 10

5-Chloro-N-(5-chloro-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide




Prepared by the method of Example 1 from 5-chloro-3-methoxy-2-pyrazinamine.

m/e 338/40/2 ($M-1^+$, 100%),

^1H NMR (D6-DMSO) δ 8.02 (1H, s), 7.67 (1H, d), 7.24 (1H, d), 3.93 (3H, s).

Example 11

5-Bromo-N-(5-bromo-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide




Prepared by the method of Example 1 from 5-bromo-2-thienylsulphonyl chloride.

m/e 426/8/430/2 ($M-1^+$, 100%),

1H NMR (D6-DMSO) δ 8.07 (1H, s), 7.62 (1H, d), 7.33 (1H, d), 3.80 (3H, s).

5 **Example 12**

5-Chloro-N-(6-chloro-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide



(a) 6-Chloro-3-methoxy-2-pyrazinamine and 3-bromo-6-methoxy-2-pyrazinamine

10 3-Bromo-6-chloro-2-pyrazinamine (0.13g), sodium methoxide (2mL of 25% in methanol) and methanol (3mL) were heated at reflux for 3 hours. The solvent was evaporated and the residue was dissolved in ethyl acetate and brine. The organic layer was separated dried ($MgSO_4$) and the solvent was evaporated to give a mixture of the sub-title compounds.

(b) 5-Chloro-N-(6-chloro-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide


15 Prepared by the method of Example 1 from a mixture of 6-chloro-3-methoxy-2-pyrazinamine and 3-bromo-6-methoxy-2-pyrazinamine. The title compound was separated and purified by chromatography on silica eluting with dichloromethane/methanol mixtures. m/e 338/40/2 ($M-1^+$, 100%),

1H NMR (D6-DMSO) δ 7.94 (1H, s), 7.67 (1H, d), 7.27 (1H, d), 3.91 (3H, s).

20

Example 13

3-Bromo-N-(5-bromo-3-methoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide




Prepared by the method of Example 1 from 3-bromo-5-chloro-2-thienylsulphonyl chloride.

m/e 460/2/4/6 ($M-1^+$, 100%),

^1H NMR (D6-DMSO) δ 7.95 (1H, s), 7.44 (1H, s), 3.93 (3H, s).

5 Example 14

N-(5-Bromo-3-methoxy-2-pyrazinyl)-3-thiophenesulphonamide




Prepared by the method of Example 1 from 3-thienylsulphonyl chloride.

m/e 350/2 ($M+1^+$, 100%),

10 ^1H NMR (D6-DMSO) δ 11.08 (1H, s), 8.36-8.34 (1H, m), 7.97 (1H, s), 7.69 (1H, ddd), 7.47 (1H, ddd), 3.92 (3H, s).

Example 15

5-Chloro-*N*-(5,6-dichloro-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide



15

(a) 3,5,6-Trichloro-2-pyrazinamine

6-Chloro-2-pyrazinamine (0.42g) and *n*-chlorosuccinimide (2.6g) in chloroform (3mL) was heated at reflux for 16 hours. Chromatography on silica eluting with dichloromethane gave the sub-title compound (0.68g).

20 (b) 5,6-Dichloro-3-methoxy-2-pyrazinamine


Prepared by the method of Example 12a using 3,5,6-trichloro-2-pyrazinamine.

(c) 5-Chloro-*N*-(5,6-dichloro-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide

Prepared by the method of Example 1 from 5,6-dichloro-3-methoxy-2-pyrazinamine.

m/e 372/4/6/8 ($M-1^+$, 100%),


¹H NMR (D6-DMSO) δ 7.67 (1H, d), 7.27 (1H, d), 3.93 (3H, s).

Example 16**5-Chloro-N-[5-bromo-3-(2-methoxyethoxy)-2-pyrazinyl]-2-thiophenesulphonamide**

2-Methoxyethanol (0.04g) was added to a stirred suspension of sodium hydride (0.05g of 60%) in 1,2-dimethoxyethane (5mL). After 10 minutes, 5-chloro-N-(3,5-dibromo-2-pyrazinyl)-2-thiophenesulphonamide (0.2g) was added. After 30 minutes, 5% aqueous citric acid and ethyl acetate were added. The organic layer was separated dried (MgSO₄) and the solvent was evaporated. Chromatography on silica eluting with hexane/ethyl acetate gave the title compound.


m/e 426/8/30 (M-1⁺, 100%),

¹H NMR (D6-DMSO) δ 8.07 (1H, s), 7.68 (1H, d), 7.24 (1H, d) 4.44-4.41 (2H, m) 3.72-3.69 (2H, m), 3.31 (3H, s).

Example 17**5-Chloro-N-[5-bromo-3-[2-(1-imidazolyl)ethoxy]-2-pyrazinyl]-2-thiophenesulphonamide**

Prepared by the method of Example 20 using 2-(1-imidazolyl)ethanol.
m/e 464/6/8 (M-1⁺, 100%),


^1H NMR (D6-DMSO) δ 8.87 (1H, s), 7.74 (2H, d), 7.50 (1H, s), 7.37 (1H, d), 7.02 (1H, d), 4.55 (4H, s).

Example 18**5-Bromo-N-(6-chloro-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide**

Prepared by the method of Example 1 from 6-chloro-3-methoxy-2-pyrazinamine and 5-bromothiophenesulphonyl chloride.

m/e 382/4/6 ($M-1^+$, 100%),


^1H NMR (D6-DMSO) δ 7.95 (1H, s), 7.64 (1H, d), 7.38 (1H, d), 3.92 (3H, s).

Example 19**5-Bromo-N-(5-chloro-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide**


Prepared by the method of Example 1 from 5-chloro-3-methoxy-2-pyrazinamine and 5-bromothiophenesulphonyl chloride.

m/e 382/4/6 ($M-1^+$, 100%),

^1H NMR (D6-DMSO) δ 8.01 (1H, s), 7.62 (1H, d), 7.33 (1H, d), 3.94 (3H, s).

Example 20**5-Chloro-*N*-[6-chloro-3-(2-furanylmethoxy)-2-pyrazinyl]-2-thiophenesulphonamide****a) 5-Chloro-*N*-(3-bromo-6-chloro-2-pyrazinyl)-2-thiophenesulphonamide**

Prepared by the method of Example 1 using 3-bromo-6-chloro-2-pyrazinamine and 5-chloro-2-thienylsulphonyl chloride.

b) 5-Chloro-*N*-[6-chloro-3-(2-furanylmethoxy)-2-pyrazinyl]-2-thiophenesulphonamide


Sodium hydride (0.04g of a 60% dispersion in oil) was added to furfuryl alcohol (0.034g) in 1,2-dimethoxyethane (1.0mL). After 5 minutes 5-chloro-*N*-(3-bromo-6-chloro-2-pyrazinyl)-2-thiophenesulphonamide (0.1g) was added and the mixture heated at 40°C.

After 16h, 5% aqueous citric acid (5.0mL) was added and the mixture extracted with ethyl acetate (2x20mL). The combined extracts were washed with brine, dried (MgSO₄) and the solvent evaporated. Chromatography on silica gel eluting with dichloromethane gave the title compound as a white solid (0.03g)

m/e 404 (M-1⁺, 100%)

¹H NMR (D6-DMSO) δ 7.97 (1H, s), 7.73 (1H, dd), 7.66 (1H, d), 7.27 (1H, d), 6.63 (1H, dd), 6.49 (1H, dd), 5.34 (2H, s)

MP 130-133°C


Example 21**5-Chloro-*N*-[6-chloro-3-(5-methyl-3-isoxazolylmethoxy)-2-pyrazinyl]-2-thiophenesulphonamide**

Prepared by the method of Example 20b using (5-methyl-3-isoxazolyl)methanol and 5-chloro-*N*-(3-bromo-6-chloro-2-pyrazinyl)-2-thiophenesulphonamide.

m/e 420 ($M-1^+$, 100%)

1H NMR (D6-DMSO) δ 7.95 (1H, s), 7.68 (1H, d), 7.28 (1H, d), 6.39 (1H, s), 5.40 (2H, s), 2.40 (3H, s)

MP 141-142°C

Example 22**5-Chloro-*N*-[6-chloro-3-(2-pyridinylmethoxy)-2-pyrazinyl]-2-thiophenesulphonamide**

Prepared by the method of Example 20b using pyridine-2-methanol and 5-chloro-*N*-(3-bromo-6-chloro-2-pyrazinyl)-2-thiophenesulphonamide.

m/e 417 ($M+1^+$, 100%)


1H NMR (D6-DMSO) δ 8.56 (1H, d), 7.90 (1H, s), 7.86 (1H, d), 7.68 (1H, d), 7.62 (1H, d), 7.39 (1H, dd), 7.27 (1H, d), 5.47 (2H, s)

MP 171-172°C

Example 23


5-Chloro-*N*-[5-methyl-3-(3-pyridinylmethoxy)-2-pyrazinyl]-2-thiophenesulphonamide

a) 5-Chloro-*N*-(3-bromo-5-methyl-2-pyrazinyl)-2-thiophenesulphonamide



Prepared by the method of Example 1 using 3-bromo-5-methyl-2-pyrazinamine and 5-chloro-2-thienylsulphonyl chloride

b) 5-Chloro-*N*-[5-methyl-3-(3-pyridinylmethoxy)-2-pyrazinyl]-2-thiophenesulphonamide



Prepared by the method of Example 20b using pyridine-3-methanol and 5-chloro-*N*-(3-bromo-5-methyl-2-pyrazinyl)-2-thiophenesulphonamide.


m/e 397 ($M+1^+$, 100%)

^1H NMR (D6-DMSO) δ 8.77 (1H, br s), 8.55 (1H, d), 7.94 (1H, dt), 7.81 (1H, br s), 7.63 (1H, d), 7.42 (1H, dd), 7.20 (1H, d), 5.41 (2H, s), 2.34 (3H, s)

MP 204-205°C

Example 24

5-Chloro-*N*-[5-methyl-3-(3-pyridazinylmethoxy)-2-pyrazinyl]-2-thiophenesulphonamide



- 5 Prepared by the method of Example 20b using pyridazine-3-methanol and 5-chloro-*N*-(3-bromo-5-methyl-2-pyrazinyl)-2-thiophenesulphonamide (Example 23a).

m/e 398 ($M+1^+$, 100%)


1H NMR (D6-DMSO) δ 11.28 (1H, br s), 9.21 (1H, dd), 7.95 (1H, d), 7.85 (1H, br s), 7.78 (1H, dd), 7.65 (1H, d), 7.21 (1H, d), 5.65 (2H, s), 2.32 (3H, s)

- 10 MP 179-181°C

Example 25


5-Chloro-*N*-[3-(2-pyridinylmethoxy)-2-pyrazinyl]-2-thiophenesulphonamide

- 15 a) 5-Chloro-*N*-(3-chloro-2-pyrazinyl)-2-thiophenesulphonamide



- 2,3-Dichloropyrazine (0.8g), 5-chloro-2-thienylsulphonamide (1.1g) and potassium carbonate (2.5g) in *N,N*-dimethylformamide (20mL) was heated at 75°C. After 16h, 5% aqueous citric acid (10.0mL) was added and the mixture extracted with ethyl acetate (2x20mL). The combined extracts were washed with brine, dried (MgSO₄) and the solvent evaporated. Chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the title compound (0.5g).

- b) 5-Chloro-*N*-[3-(2-pyridinylmethoxy)-2-pyrazinyl]-2-thiophenesulphonamide



Prepared by the method of Example 20b using pyridine-2-methanol and 5-chloro-*N*-(3-chloro-2-pyrazinyl)-2-thiophenesulphonamide with reaction mixture heated at 70°C for 4h.
m/e 383 ($M+1^+$, 100%)


^1H NMR (D6-DMSO) δ 8.56 (1H, d), 7.91 (1H, br s), 7.87-7.80 (2H, m), 7.70 (1H, d), 7.61 (1H, d), 7.35-7.30 (1H, m), 7.23 (1H, d), 5.48 (2H, s)

MP 109-110°C

10

Example 26

5-Chloro-*N*-(3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide




15 5-Chloro-*N*-(3-chloro-2-pyrazinyl)-2-thiophenesulphonamide (Example 25a) (0.03g) in sodium methoxide in methanol (1.5mL of a 10% solution) was heated at 85 °C. After 4h, 5% aqueous citric acid (10.0mL) was added and the mixture extracted with ethyl acetate (2x30mL). The combined extracts were washed with brine, dried (MgSO_4) and the solvent evaporated. Chromatography on silica gel eluting with ethyl acetate/isohexane mixtures
20 gave the title compound as a white solid (0.026g)

m/e 304 ($M-1^+$, 100%)

^1H NMR (D6-DMSO) δ 7.90-7.80 (2H, m), 7.68 (1H, d), 7.23 (1H, d), 3.91 (3H, s)

MP 119-120°C

Example 27**5-Chloro-N-(5,6-dimethyl-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide**


Prepared by the method of Example 1 using 3-methoxy-5,6-dimethyl-2-pyrazinamine and 5-chloro-2-thienylsulphonyl chloride.

m/e 334 ($M+1^+$, 100%)

^1H NMR (CDCl_3) δ 7.69 (1H, d), 7.44 (1H, br s), 6.90 (1H, d), 3.94 (3H, s), 2.40 (3H, s),

2.34 (3H, s)


MP 95-96°C

Example 28**N-[5-Chloro-3-methoxy-2-pyrazinyl]-5-methyl-2-thiophenesulphonamide**

Prepared by the method of Example 1 using 5-methylthiophenesulphonyl chloride and 5-chloro-3-methoxy-2-pyrazinamine.

m/e 318 ($M-1^+$, 100%)

^1H NMR ($\text{D}_6\text{-DMSO}$) δ 11.27 (1H, br s), 7.96 (1H, s), 7.61 (1H, d), 6.87 (1H, d), 3.93 (3H, s), 2.48 (3H, s)

Example 29**5-Methyl-*N*-[5-methyl-3-methoxy-2-pyrazinyl]-2-thiophenesulphonamide**

- 5 Prepared by the method of Example 1 using 5-methylthiophenesulphonyl chloride and 3-methoxy-5-methyl-2-pyrazinamine.


m/e 298 ($M-1^+$, 100%)

1H NMR (D6-DMSO) δ 10.79 (1H, s), 7.72 (1H, s), 7.57 (1H, d), 6.86 (1H, d), 3.88 (3H, s), 2.48 (3H, s), 2.31 (3H, s).

10

Example 30***N*-[5-[(2-Aminoethyl)sulpanyl]-3-methoxy-2-pyrazinyl]-5-chloro-2-thiophenesulphonamide**

- 15 a) *N*-[5-bromo-3-methoxy-2-pyrazinyl]-5-chloro-*N*-[(2-trimethylsilanyloxy)methyl]-2-thiophenesulphonamide



A mixture *N*-(5-Bromo-3-methoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide

(Example 1) (0.40g), diisopropylethylamine (0.26g) and [2-


- 20 (chloromethoxy)ethyl]trimethylsilane (0.25g) in dichloromethane (50mL) was stirred at room temperature. After 2h, the solution was washed with water, dried ($MgSO_4$) and

evaporated. Chromatography on silica gel eluting with ethyl acetate/isohexane mixtures gave the title compound as a white solid (0.40g).

¹H NMR (CDCl₃) δ 8.19 (1H, s), 7.58 (1H, d), 7.00 (1H, d), 5.2 (2H, s), 4.1 (3H, s), 3.40-3.60 (2H, m), 0.75-0.85 (2H, m), 0.0 (9H, s).

5

b) *N*-[5-[(2-Aminoethyl)sulpanyl]-3-methoxy-2-pyrazinyl]-5-chloro-2-thiophenesulphonamide



The product from step 30a (0.26g), 2-mercaptoethylamine hydrochloride (0.07g) and cesium carbonate (0.41g) in acetonitrile (10ml) was stirred at room temperature and under nitrogen for 20 hours. The reaction mixture was partitioned between ethyl acetate and water. The ethyl acetate solution was then washed with brine, dried (MgSO₄) and evaporated. Chromatography on silica eluting with methanol/dichloromethane, 1/10 gave *N*-[5-[(2-Aminoethyl)sulpanyl]-3-methoxypyrazin-2-yl]-5-chloro-*N*-(2-trimethylsilanylethoxy)methyl-2-thiophenesulphonamide (0.2g).

15

This compound was dissolved in trifluoroacetic acid (5mL) at room temperature. After 5 minutes, toluene (30ml) was added and the mixture evaporated. Diethyl ether was added and the product crystallised to give a white solid (0.17g).

m/e 379 (M-1⁺)


¹H NMR (D₆-DMSO) δ 7.90 (2H, br s), 7.90 (1H, s), 7.63 (1H, d), 7.23 (1H, d), 3.95 (3H, s), 3.30 (2H, t), 3.11 (2H, m).

20

MP 192-194°C

Example 31

25 **5-Chloro-*N*-[5-cyano-3-methoxy-2-pyrazinyl]-2-thiophenesulphonamide**



The product from Example 1 (0.1g), zinc cyanide (0.02g) and tetrakis(triphenylphosphine)palladium (0) (0.015g) in dry *N,N*-dimethylformamide (5mL) (deoxygenated by bubbling nitrogen through the solution for 10 minutes) was heated under nitrogen at 80°C for 9 hours and then the reaction mixture was evaporated to dryness under reduced pressure. Chromatography on silica eluting with ethyl acetate/*iso*-hexanes, 1/1 gave the title compound (0.05g).


m/e 329 ($M-1^+$)

1H NMR (DMSO) δ 8.41 (2H, s), 7.70 (1H, d), 7.25 (1H, d), 3.93 (3H, s).

MP 218-219°C

Example 32

N-[5-Bromo-3-(4-methoxybenzyloxy)pyrazin-2-yl]-5-chloro-2-thiophenesulphonamide



Prepared by the method of Example 20b using 5-chloro-*N*-(3,5-dibromo-2-pyrazinyl)-2-thiophenesulphonamide (Example 8) (0.32g) and 4-methoxybenzylalcohol (0.1g) to give the product (0.32g).

m/e 490 (M+1⁺)

¹H NMR (DMSO) δ 8.09 (1H, s), 7.65 (1H, d), 7.45 (2H, d), 7.23 (1H, d), 6.95 (2H, d), 5.30 (2H, d), 3.76 (3H, s).

Pharmacological Data

FMAT Whole cell binding assay

5 Cells

CHO-K1 cells stably expressing the human recombinant CCR4 receptor (Euroscreen; Brussels, Belgium) were cultured in NUT.MIX.F_12(HAM) medium with glutamax-1, containing 10% (v/v) foetal bovine serum and 400 $\mu\text{g ml}^{-1}$ geneticin.

10

Cells were harvested at approximately 70% confluence by treatment with a cell dissociation buffer, and seeded at 5×10^3 cells/100 μl culture medium into wells of a black Costar clear-bottomed 96-well microtitre plates. Plates were incubated overnight at 37°C in 5% CO_2 and used the following day.

15

ASSAY

Before use, the cell plates were washed twice with 100 μl Hanks balanced salt solution (HBSS). To each well was then added 65 μl of HBSS, 10 μL of 10% DMSO in HBSS \pm test compound and then 25 μL of 2.8 nM FB-MDC (Applied Biosystems). This
20 fluorescent probe was prepared from a 10 μM stock in 0.08% (v/v) TFA/16% (v/v) acetonitrile, diluted into HBSS.

After two hours incubation in the dark at room temperature, the plates were analysed in an FMAT8100 reader (Applied Biosystems) to measure fluorescence that was associated with
25 binding of FB-MDC to the cells. Compound activity was determined as an pIC_{50} [log(concentration of compound that results in 50% inhibition)], comparing fluorescence in control and background wells.

Typical Data

30

Fluorescence (ctrl) = 1200

Fluorescence (bkg) = 0


			Mean
35	Example 1	pIC_{50}	7.4
	Example 23	pIC_{50}	8.0

Example 16	pIC ₅₀	6.2
------------	-------------------	-----

All the compounds of the examples have a pIC₅₀ of less than 5.0.

CLAIMS

1. A compound of formula (I) and pharmaceutically acceptable salts or solvates thereof:



(I)

in which:

R¹, R² and R³ are independently hydrogen, halogen, cyano, CF₃, or C₁₋₆ alkyl;

R⁴ is halogen, CO₂R¹²,

C₁₋₆ alkoxy where the alkyl group may form a 3-6 membered saturated ring or may be substituted with 1-3 fluorine atoms or a cyano group;

C₃₋₆ alkenyloxy or C₃₋₆ alkynyloxy where either may be optionally substituted with hydroxy or NR¹⁴R¹⁵;

OC₁₋₆ alkyl-X-C₁₋₆ alkyl where the alkyl groups may form a 3-6 membered saturated ring;

OC₁₋₆ alkylR¹¹, or OC₂₋₆ alkyl-X-R¹¹ where the alkyl group may form a 3-6 membered saturated ring and is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR¹⁴R¹⁵, SR¹³, S(O)₂R¹³, S(O)R¹³;

OC₁₋₆ alkylR¹⁶;

R⁵ and R⁶ are independently hydrogen, cyano, halogen, CO₂R¹², CONR¹⁴R¹⁵;

C₁₋₆ alkyl optionally substituted by hydroxy, NR¹⁴R¹⁵, or 1-3 fluorines;

C₁₋₆ alkylR¹¹ or XCH(R¹¹)C₁₋₆ alkyl or XCH(R¹⁶)C₁₋₆ alkyl where the alkyl group may be optionally substituted with 1-3 groups selected from hydroxy, and NR¹⁴R¹⁵;

NR¹⁴R¹⁵; N(R¹¹)R¹¹; X-(CH₂)_qNR¹⁴R¹⁵; (CH₂)_nNR¹⁴R¹⁵;

C₃₋₆ alkynyl or C₃₋₆ alkenyl optionally branched and optionally substituted with 1-3 groups selected from hydroxy, cyano, halogen and =O;

R¹¹; X-R¹¹; X-R¹²; X-(C₁₋₆)alkylR¹⁶; X-R¹⁶; X-(CH₂)_nCO₂R¹²; X-(CH₂)_nCONR¹⁴R¹⁵;

X-(CH₂)_nR¹¹; X-(CH₂)_nCN; X-(CH₂)_qOR¹²; (CH₂)_nOR¹²;

(CH₂)_n-X-R¹¹; X-(CH₂)_qNHC(O)NHR¹²; X-(CH₂)_qNHC(O)R¹²;

X-(CH₂)_qNHS(O)₂R¹²; X-(CH₂)_qNHS(O)₂R¹¹; X-(C₃₋₆)alkenyl; X-(C₃₋₆)alkynyl;

n is 1, 2, 3, 4 or 5;

q is 2, 3, 4, 5 or 6;

X is NR¹³, O, S, S(O), S(O)₂;

R¹¹ is an aryl group or a 5-7 membered heteraromatic ring containing 1-4 heteroatoms selected from nitrogen, oxygen or sulphur each of which can be optionally substituted by 1-3 groups selected from halogen, C(O)NR¹⁴R¹⁵, C(O)OR¹², hydroxy, =O, =S, CN, NO₂,

NR¹⁴R¹⁵, X(CH₂)_qNR¹⁴R¹⁵, (CH₂)_nNR¹⁴R¹⁵, (CH₂)_nOH, SR¹³, S(O)R¹³, S(O)₂R¹³

C₁₋₆ alkyl-X-C₁₋₆ alkyl, C₁₋₆ alkyl or C₁₋₆ alkoxy where the alkyl group may form a 3-6 membered ring or is optionally substituted with 1-3 groups selected from hydroxy, halogen, NR¹⁴R¹⁵, SR¹³, S(O)R¹³, S(O)₂R¹³;

R¹² and R¹³ are independently hydrogen or C₁₋₆ alkyl where the alkyl group may be substituted with 1-3 fluorine atoms or may form a saturated 3-6 membered ring;

R¹⁴ and R¹⁵ are independently hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl or (CH₂)_qOH,

or R¹⁴ and R¹⁵ together with the nitrogen atom to which they are attached form a 4-8 membered saturated ring containing 1-3 heteroatoms selected from nitrogen, oxygen and sulphur, and optionally substituted by C₁₋₆ alkyl, C₁₋₆ alkyl-OH, or hydroxy; and

5 R¹⁶ is a 4-8 membered saturated ring containing 1-3 heteroatoms selected from nitrogen, oxygen or sulphur and optionally substituted with 1-3 groups selected from hydroxy, cyano, halogen and =O.

2. A compound according to claim 1 in which the thienyl moiety is linked to the
10 sulphonamide at the 2-position of the thiophene ring.

3. A compound according to claim 1 or 2 in which R¹, R² and R³ are all hydrogen or two are hydrogen and the other is chloro, bromo or methyl.

15 4. A compound according to any one of claims 1 to 3 in which R⁴ is C₁₋₆ alkoxy, phenoxy, 2-furanylmethoxy, bromo, 2-methoxyethoxy, (5-methyl-3-isoxazolyl)methoxy, 2-pyridylmethoxy, 3-pyridazinylmethoxy, 2-(1-imidazolyl)ethoxy or 4-methoxyphenylmethoxy.

20 5. A compound according to any one of claims 1 to 4 in which R⁵ is hydrogen, halogen, phenyl, C₁₋₆ alkyl, cyano or 2-aminothioethanol.

6. A compound according to any one of claims 1 to 5 in which R⁶ is hydrogen, C₁₋₆ alkyl or halogen.

25

7. A compound according to claim 1 which is:

N-(5-Bromo-3-methoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide

N-(5-Bromo-3-ethoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide

N-(5-Bromo-3-methoxy-2-pyrazinyl)-4,5-dichloro-2-thiophenesulphonamide

30 5-Chloro-N-(3-methoxy-5-phenyl-2-pyrazinyl)-2-thiophenesulphonamide

N-(5-Bromo-3-phenoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide

N-(5-Bromo-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide

N-[5-Bromo-3-(2-furanylmethoxy)-2-pyrazinyl]-5-chloro-2-thiophenesulphonamide

5-Chloro-N-(3,5-dibromo-2-pyrazinyl)-2-thiophenesulphonamide

35 5-Chloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-2-thiophenesulphonamide

5-Chloro-N-(5-chloro-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide

- 5-Bromo-N-(5-bromo-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide
 5-Chloro-N-(6-chloro-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide
 3-Bromo-N-(5-bromo-3-methoxy-2-pyrazinyl)-5-chloro-2-thiophenesulphonamide
 N-(5-Bromo-3-methoxy-2-pyrazinyl)-3-thiophenesulphonamide
 5-Chloro-N-(5,6-dichloro-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide
 5-Chloro-N-[5-bromo-3-(2-methoxyethoxy)-2-pyrazinyl]-2-thiophenesulphonamide
 5-Chloro-N-[5-bromo-3-[2-(1-imidazolyl)ethoxy]-2-pyrazinyl]-2-
 thiophenesulphonamide
 5-Bromo-N-(6-chloro-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide
 5-Bromo-N-(5-chloro-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide
 5-Chloro-N-[6-chloro-3-(2-furanylmethoxy)-2-pyrazinyl]-2-thiophenesulphonamide
 5-Chloro-N-[6-chloro-3-(5-methyl-3-isoxazolylmethoxy)-2-pyrazinyl]-2-
 thiophenesulphonamide
 5-Chloro-N-[6-chloro-3-(2-pyridinylmethoxy)-2-pyrazinyl]-2-thiophenesulphonamide
 5-Chloro-N-[5-methyl-3-(3-pyridinylmethoxy)-2-pyrazinyl]-2-thiophenesulphonamide
 5-Chloro-N-[5-methyl-3-(3-pyridazinylmethoxy)-2-pyrazinyl]-2-
 thiophenesulphonamide
 5-Chloro-N-[3-(2-pyridinylmethoxy)-2-pyrazinyl]-2-thiophenesulphonamide
 5-Chloro-N-(3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide
 5-Chloro-N-(5,6-dimethyl-3-methoxy-2-pyrazinyl)-2-thiophenesulphonamide
 N-[5-Chloro-3-methoxy-2-pyrazinyl]-5-methyl-2-thiophenesulphonamide
 5-Methyl-N-[5-methyl-3-methoxy-2-pyrazinyl]-2-thiophenesulphonamide
 N-[5-((2-Aminoethyl)sulpanyl)-3-methoxypyrazin-2-yl]-5-chloro-2-
 thiophenesulphonamide
 5-Chloro-N-[5-cyano-3-methoxypyrazin-2-yl]-2-thiophenesulphonamide
 N-[5-Bromo-3-(4-methoxybenzyloxy)pyrazin-2-yl]-5-chloro-2-
 thiophenesulphonamide
 and pharmaceutically acceptable salts and solvates thereof.

8. A compound of formula (IA) in which:
 R^1 , R^2 and R^3 are independently hydrogen, C_{1-6} alkyl or halogen;
 R^4 is halogen, C_{1-6} alkoxy or OR^9 ;
 R^5 and R^6 are independently hydrogen, halogen, C_{1-6} alkoxy, C_{1-6} alkylthio, cyano, R^9 ,
 OR^9 , NR^9R^{10} , SR^9 , $S(CH_2)_nCO_2H$, $S(CH_2)_nCO_2R^{12}$, $S(CH_2)_nCONR^{12}R^{13}$, $S(CH_2)_nR^{11}$
 or a 5- to 7-membered heteroaromatic or saturated ring containing 1 to 3 heteroatoms
 selected from nitrogen, oxygen and sulphur;

n is 1, 2 or 3;

R⁹ and R¹⁰ are independently hydrogen, C₁₋₆ alkyl optionally substituted by hydroxy, C₁₋₆ alkoxy or NHCOC₁₋₆ alkyl, or R⁹ and R¹⁰ are optionally substituted aryl, C₁₋₆ alkyl-aryl or C₁₋₆ alkyl-R¹¹ or R⁹ and R¹⁰ together with the nitrogen atom to which they are attached form a 4- to 8-membered saturated ring containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulphur and optionally substituted by C₁₋₆ alkyl or C₁₋₆ alkyl-OH; and

R¹¹ is a 5- to 7-membered heteraromatic ring containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulphur and optionally substituted by C₁₋₆ alkyl; and

R¹² and R¹³ are independently hydrogen or C₁₋₆ alkyl.


9. A compound according to claim 8 in which R¹, R² and R³ are all hydrogen or two are hydrogen and the other is chloro or methyl.

10. A compound according to claim 8 or 9 in which R⁴ is C₁₋₆ alkoxy, phenoxy, 2-furanylmethoxy, bromo, 2-methoxyethoxy, (5-methyl-3-isoxazolyl)methoxy, 2-pyridylmethoxy, 3-pyridazinylmethoxy, methoxy or 2-(1-imidazolyl)ethoxy.

11. A compound according to any one of claims 8 to 10 in which R⁵ is halogen, phenyl or C₁₋₆ alkyl.


12. A compound according to any one of claims 8 to 11 in which R⁶ is hydrogen, C₁₋₆ alkyl and halogen.

13. A process for the preparation of a compound of formula (I) which comprises reaction of a compound of formula (II):



(II)

where R⁴, R⁵ and R⁶ are as defined in formula (I) or are protected derivatives thereof with a compound of formula (III):



(III)

where R¹, R² and R³ are as defined in formula (I) or are protected derivatives thereof
 and LG is a leaving group,
 and optionally thereafter

- removing any protecting groups,
- forming a pharmaceutically acceptable salt.

14. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

15. A process for the preparation of a pharmaceutical composition as claimed in claim 2 which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 with a pharmaceutically acceptable adjuvant, diluent or carrier.

16. A compound of formula (I), or a pharmaceutically-acceptable salt or solvate thereof, as claimed in claim 1 for use in therapy.

17. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1 in the manufacture of a medicament for use in therapy.

18. A method of treating a chemokine mediated disease wherein the chemokine binds to one or more chemokine receptors, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1.

19. A method according to claim 18 in which the chemokine receptor belongs to the CCR chemokine receptor subfamily.

20. A method according to claim 18 or 19 in which the chemokine receptor is the CCR4 receptor.

21. A method of treating an inflammatory disease in a patient suffering from, or at risk of, said disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as claimed in claim 1.
22. A method according to claim 21, wherein the disease is asthma.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 02/02355

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 409/12, C07D 409/14, C07D 413/14, A61K 31/497, A61P 11/06, A61P 29/00
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CHEM.ABS.DATA, EPO-INTERNAL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9813366 A1 (TEXAS BIOTECHNOLOGY CORPORATION), 2 April 1998 (02.04.98), see particularly page 31, line 22 and claim 15, line 11 - line 30 --	1-22
A	EP 0713875 A1 (F. HOFFMANN-LA ROCHE AG), 29 May 1996 (29.05.96) -- -----	1-22

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

4 April 2003

Date of mailing of the international search report

09-04-2003

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

NEBIL GECER/BS

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

Int. al application No.

PCT/SE 02/02355

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9813366 A1	02/04/98	AP 9901471 D	00/00/00
		AU 736269 B	26/07/01
		AU 4505997 A	17/04/98
		BR 9711550 A	18/01/00
		CN 1231664 A	13/10/99
		CZ 9900854 A	16/06/99
		EP 0946552 A	06/10/99
		IL 128145 D	00/00/00
		JP 2000507607 T	20/06/00
		JP 2002308875 A	23/10/02
		KR 2000048681 A	25/07/00
		NO 991388 A	27/05/99
		NZ 334797 A	23/02/01
		PL 332323 A	30/08/99
		SK 36599 A	14/02/00
		TR 9900705 T	00/00/00
		US 5962490 A	05/10/99
		US 6331637 B	18/12/01
		US 6420567 B	16/07/02
		US 2002091272 A	11/07/02
EP 0713875 A1	29/05/96	SE 0713875 T3	
		AT 199905 T	15/04/01
		AU 691353 B	14/05/98
		AU 3789595 A	30/05/96
		CA 2162630 A	26/05/96
		CN 1064965 B	25/04/01
		CN 1132751 A	09/10/96
		CZ 289920 B	17/04/02
		CZ 9503088 A	16/07/97
		DE 59509107 D	00/00/00
		DK 713875 T	11/06/01
		ES 2156179 T	16/06/01
		FI 955669 A	26/05/96
		GR 3036065 T	28/09/01
		HK 1012345 A	00/00/00
		HU 75030 A	28/03/97
		HU 9503311 D	00/00/00
		IL 116064 A	29/06/00
		JP 2755565 B	20/05/98
		JP 8208625 A	13/08/96
		NO 307606 B	02/05/00
		NO 954718 A	28/05/96
		NZ 280495 A	20/12/96
		PT 713875 T	28/09/01
		RU 2162084 C	20/01/01
		TW 394763 B	00/00/00
		BR 9505528 A	04/11/97
		PL 311487 A	27/05/96
		SG 33601 A	18/10/96
		TR 960498 A	00/00/00
		US 5837708 A	17/11/98
		WO 9616963 A	06/06/96
		ZA 9509808 A	27/05/96

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE02/02355

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **18-22**
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Int ☐ I application No.
PCT/SE02/02355

Claims 18-22 relate to methods of treatment of the human or animal body by surgery or by therapy/diagnostic methods practised on the human or animal body/Rule. 39.1.(iv)). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.